“Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy” (2022) Farmeconomia. Health economics and therapeutic pathways, 23(1). doi:10.7175/fe.v23i1.1539.